Product Data Sheet

AB-680

Cat. No.: HY-125286 CAS No.: 2105904-82-1 Molecular Formula: $C_{20}H_{24}CIFN_{4}O_{9}P_{2}$

Molecular Weight: 580.82 CD73 Target:

Pathway: Immunology/Inflammation -20°C, stored under nitrogen Storage:

* In solvent: -80°C, 1 years; -20°C, 6 months (stored under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 200 mg/mL (344.34 mM; Need ultrasonic)

H₂O: 5 mg/mL (8.61 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.7217 mL	8.6085 mL	17.2170 mL
	5 mM	0.3443 mL	1.7217 mL	3.4434 mL
	10 mM	0.1722 mL	0.8609 mL	1.7217 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 7.5 mg/mL (12.91 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 7.5 mg/mL (12.91 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 7.5 mg/mL (12.91 mM); Clear solution
- 4. Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (4.30 mM); Clear solution
- 5. Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (4.30 mM); Suspended solution; Need ultrasonic
- 6. Add each solvent one by one: 1% DMSO >> 99% saline Solubility: ≥ 0.5 mg/mL (0.86 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a K_i of 4.9 pM for hCD73,

	displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity ^[1] .
IC ₅₀ & Target	Ki: 4.9 pM (hCD73) ^[1] IC50: 43 pM (Soluble hCD73) ^[1]
In Vitro	AB-680 (AB680) inhibits soluble hCD73 with an IC $_{50}$ of 0.043 nM, also inhibits hCD73 in CHO cells, suppresses CD73 in human, mouse CD8 $^+$ T Cells and hPBMC, with IC $_{50}$ s of 0.070, 0.008, 0.66 and 0.011 nM, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Commun. 2023 Jun 8;14(1):3364.
- Adv Sci (Weinh). 2023 Oct 22:e2302498.
- J Immunother Cancer. 2021 Jul;9(7):e002503.
- Cancer Immunol Res. 2022 Nov 21;CIR-22-0260.
- Front Immunol. 2022, 13: Online ahead of print.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES			

[1]. Lawson KV, et al. Discovery and Characterization of AB680, a Potent and Selective Small-Molecule CD73 Inhibitor for Cancer Immunotherapy.

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com